BAM Management
Latest statistics and disclosures from BAM Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Oncothyreon, BioSante Pharmaceuticals, Genvec, RXi Pharmaceuticals Corporation, and represent 100.00% of BAM Management's stock portfolio.
- Added to shares of these 3 stocks: Oncothyreon, BioSante Pharmaceuticals, Genvec.
- Reduced shares in these 1 stock: RXi Pharmaceuticals Corporation.
- BAM Management was a net buyer of stock by $5.2M.
- BAM Management has $13M in assets under management (AUM), dropping by 20.96%.
- Central Index Key (CIK): 0001463541
Portfolio Holdings for BAM Management
BAM Management holds 4 positions in its portfolio as reported in the September 2011 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Oncothyreon | 57.6 | $7.5M | +66% | 1.2M | 5.98 |
|
| BioSante Pharmaceuticals | 38.6 | $5.0M | +89% | 2.2M | 2.28 |
|
| Genvec | 2.4 | $313k | +20% | 109k | 2.87 |
|
| RXi Pharmaceuticals Corporation | 1.4 | $179k | -51% | 177k | 1.01 |
|
Past Filings by BAM Management
SEC 13F filings are viewable for BAM Management going back to 2010
- BAM Management 2011 Q3 filed Nov. 14, 2011
- BAM Management 2011 Q2 filed Aug. 15, 2011
- BAM Management 2011 Q1 filed May 16, 2011
- BAM Management 2010 Q4 filed Feb. 14, 2011